Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 1;49(2):225-233.
doi: 10.1177/2168479014555912.

INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy

Katherine Huppler Hullsiek  1 , Jonathan M Kagan  2 , Nicole Engen  1 , Jesper Grarup  3 , Fleur Hudson  4 , Eileen T Denning  1 , Catherine Carey  5 , David Courtney-Rodgers  5 , Elizabeth B Finley  6 , Per O Jansson  3 , Mary T Pearson  3 , Dwight E Peavy  7 , Waldo H Belloso  8
Affiliations

INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy

Katherine Huppler Hullsiek et al. Ther Innov Regul Sci. .

Abstract

Background: Trial monitoring protects participant safety and study integrity. While monitors commonly go on-site to verify source data, there is little evidence that this practice is efficient or effective. An ongoing international HIV treatment trial (START) provides an opportunity to explore the usefulness of different monitoring approaches.

Methods: All START sites are centrally monitored and required to follow a local monitoring plan requiring specific quality assurance activities. Additionally, sites were randomized (1:1) to receive, or not receive, annual on-site monitoring. The study will determine if on-site monitoring increases the identification of major protocol deviations (eligibility or consent violations, improper study drug use, primary or serious event underreporting, data alteration or fraud).

Results: The START study completed enrollment in December 2013, with planned follow-up through December 2016. The monitoring study is ongoing at 196 sites in 34 countries. Results are expected when the START study concludes in December 2016.

Keywords: Data monitoring; centralized monitoring; clinical trials; on-site monitoring; quality assurance.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors report no conflicts of interest

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. Baigent C, Harrell F, Buyse M, et al. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials. 2008;5:49–55. - PubMed
    1. US Food and Drug Administration. [accessed 6 May 2014];Guidance for Industry Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring. 2013 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
    1. European Medicines Agency. [accessed 6 May 2014];Reflection paper on risk based quality management in clinical trials. 2011 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin....
    1. Usher RW. PhRMA BioResearch Monitoring Committee Perspective on Acceptable Approaches for Clinical Trial Monitoring. Drug Information Journal. 2010;44:477–483.
    1. Bakobaki J, Joffe N, Burdett S, et al. A systematic search for reports of site monitoring technique comparisons in clinical trials. Clin Trials. 2012;9:777–780. - PubMed